

**Carrier Screening Market by Product and Service, Type (Expanded (Customized, Predesigned) Targeted Diseases, Medical condition (Hematologic, Pulmonary), Technology (DNA Sequencing, PCR), End user, Region - Global Forecast to 2028**

Market Report | 2024-01-31 | 224 pages | MarketsandMarkets

**AVAILABLE LICENSES:**

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

**Report description:**

The global Carrier Screening Market is expected to reach USD 5.4 Billion by 2028 from USD 2.2 Billion in 2023, at a CAGR of 19.7% during the forecast period. Market is driven by factors such as Ongoing advancements in genetic testing technologies, such as next-generation sequencing (NGS), improve the efficiency, accuracy, and cost-effectiveness of carrier screening, The increasing prevalence of genetic disorders, coupled with a greater understanding of the genetic basis of various conditions On the other hand, The demand for genetic counseling services often exceeds the available resources. A shortage of genetic counselors can hinder the delivery of comprehensive counseling to individuals undergoing carrier screening, potentially limiting the understanding and interpretation of results.

"The Neurological Conditions accounted for the second largest market share in the carrier screening market product' s market, during the forecast period"

Based on the Medical Conditions, Carrier Screening Market is classified into Hematologic Conditions, Pulmonary Conditions, Neurological Conditions, and Others. In 2022, Neurological Conditions accounted for a sizable market share because Many neurological disorders have a genetic component. Understanding the genetic basis of conditions such as Huntington's disease, amyotrophic lateral sclerosis (ALS), and certain forms of epilepsy can be crucial for assessing the risk of passing on these conditions to future generations. Likewise, Carrier screening for neurological conditions allows for early detection of genetic risk factors. Early identification of carriers provides an opportunity for individuals and couples to make informed reproductive decisions and consider interventions or therapies early in the planning stages.

"PCR technology segment accounted for the second largest market share"

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Based on type on technology, the carrier screening market is segmented into DNA Sequencing, PCR, DNA Microarray, and Other. The PCR technology segment accounted for the second largest market share in 2022., due to its variety of applications such as PCR technology is known for its high sensitivity and specificity in amplifying and detecting specific DNA sequences. This accuracy is crucial in carrier screening to reliably identify carriers of genetic mutations associated with various disorders, likewise, PCR allows for the amplification of multiple target DNA sequences in a single reaction, a feature known as multiplexing. This capability is valuable in carrier screening,

"APAC region accounted for the third highest CAGR"

The global Carrier Screening market is divided into four regions: North America, Asia-Pacific, Europe, and Rest of the World. According to the regional analysis, the Asia-Pacific region is likely to retain a considerable market share in 2022 and the future. The Asia-Pacific market is being propelled by an rising cases of rare disease, rising in healthcare expenditure, rising in awareness about early disease diagnosis.

"Europe is estimated to register the second highest CAGR during the forecast period."

In this report, the Carrier Screening market is segmented into four major regional segments: North America, Europe, Asia Pacific, Rest of the world. The market in Europe is projected to register the second highest growth rate during the forecast period. The growth in this market is due to Europe has a strong tradition of research and academic excellence, the rising incidence of genetic and rare diseases, government funding for research and healthcare in many European countries supports the development and adoption of advanced diagnostic technologies such as carrier screening.

The primary interviews conducted for this report can be categorized as follows:

- By Company Type: Tier 1 - 32%, Tier 2 - 44%, and Tier 3 - 24%
- By Designation: C-level - 30%, D-level - 34%, and Others - 36%
- By Region: North America - 40%, Europe - 28%, Asia Pacific - 20%, and the Rest of the World - 12%

Lits of Companies Profiled in the Report:

Invitae Corporation. (US)  
Fulgent Genetics.(US)  
Eurofins Scientific (Germany)  
OPKO Health, Inc.(US)  
Thermo Fisher Scientific Inc.(US)  
Quest Diagnostics Incorporated (US)  
Myriad Genetics, Inc (US)  
Illumina, Inc.(US)  
Natera, Inc.(Italy)  
Laboratory Corporation of America Holdings.(US)  
CENTOGENE N.V.(Germany)  
DiaSorin S.p.A.(Italy)  
BGI (China)  
Otogenetics (US)  
GeneTech (India)  
Signature Diagnostics Inc.(US)  
MedGenome (US)  
Ambry Genetics.(US)  
Asper Biogene (Estonia)  
LifeLabs Genetics (Canada)  
EasyDNA (US)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

LifeCell (India)  
CNC Path Lab (India)  
Oxy-Gen Laboratory LLC (US)  
Mitera (US)

#### Research Coverage:

This report studies the Carrier Screening market based on Product & Service, Type, Medical Condition, Technology, End User, and Region. The report also analyses factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total Carrier Screening market. The report forecasts the revenue of the market segments with respect to four major regions.

#### Reasons to Buy the Report:

The report provides insights on the following pointers:

**Market Drivers:** Comprehensive information about driving factors of the markets. The report analyses the markets drivers across key geographic regions.

**Market Penetration:** Comprehensive information on Carrier Screening Market products offered by the top 25 players in the market. The report analyses the Carrier Screening market by Product & Service, Type, Medical Condition, Technology, End User, and Region.

**Market Development:** Comprehensive information about lucrative emerging markets. The report analyses the markets for various securement devices across key geographic regions.

**Market Diversification:** Exhaustive information about untapped geographies, recent developments, and investments in the Carrier Screening market

**Competitive Assessment:** In-depth assessment of market shares and strategies of the leading players in the Carrier Screening market

**Market Position:** It will upkeep stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies.

#### Table of Contents:

1	INTRODUCTION	31
1.1	STUDY OBJECTIVES	31
1.2	MARKET DEFINITION	31
1.3	INCLUSIONS & EXCLUSIONS	32
1.4	MARKET SCOPE	33
1.4.1	MARKETS COVERED	33
1.4.2	REGIONS COVERED	33
1.4.3	YEARS CONSIDERED	34
1.4.4	CURRENCY CONSIDERED	34
1.5	STAKEHOLDERS	34
1.6	SUMMARY OF CHANGES	35
1.6.1	RECESSION IMPACT: CARRIER SCREENING MARKET	35
2	RESEARCH METHODOLOGY	36
2.1	RESEARCH DATA	36
FIGURE 1	RESEARCH DESIGN	36
2.1.1	SECONDARY DATA	36

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

FIGURE 2	KEY SECONDARY SOURCES	38
2.1.2	PRIMARY DATA	39
FIGURE 3	PRIMARY SOURCES	39
2.1.2.1	Key data from primary sources	39
2.1.2.2	Key industry insights	40
2.1.2.3	Breakdown of primary interviews	41
FIGURE 4	BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS	41
FIGURE 5	BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION	41
2.2	MARKET ESTIMATION	41
2.2.1	REVENUE MAPPING-BASED MARKET ESTIMATION	42
FIGURE 6	MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH	42
FIGURE 7	MARKET SIZE ESTIMATION: CARRIER SCREENING MARKET	43
2.2.2	GROWTH FORECAST	44
FIGURE 8	CAGR PROJECTION: SUPPLY-SIDE ANALYSIS	44
FIGURE 9	TOP-DOWN APPROACH	45
2.3	MARKET BREAKDOWN AND DATA TRIANGULATION	46
FIGURE 10	DATA TRIANGULATION METHODOLOGY	46
2.4	RESEARCH LIMITATIONS	47
2.5	MARKET SHARE ANALYSIS	47
2.6	STUDY ASSUMPTIONS	47
2.7	RISK ASSESSMENT	48
TABLE 1	RISK ASSESSMENT: CARRIER SCREENING MARKET	48
2.8	IMPACT OF ECONOMIC RECESSION ON CARRIER SCREENING MARKET	49
3	EXECUTIVE SUMMARY	50
FIGURE 11	CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)	50
FIGURE 12	CARRIER SCREENING MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)	51
FIGURE 13	CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2023 VS. 2028 (USD MILLION)	51
FIGURE 14	CARRIER SCREENING MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)	52
FIGURE 15	CARRIER SCREENING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)	53
FIGURE 16	CARRIER SCREENING MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)	53
4	PREMIUM INSIGHTS	55
4.1	CARRIER SCREENING MARKET OVERVIEW	55
FIGURE 17	GROWING PREVALENCE OF GENETIC DISORDERS TO DRIVE MARKET	55
4.2	CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2023-2028	55
FIGURE 18	PREDESIGNED PANEL TESTING SEGMENT TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD	55
4.3	NORTH AMERICA: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE AND COUNTRY, 2023	56
FIGURE 19	US AND PRODUCTS TO DOMINATE NORTH AMERICAN CARRIER SCREENING MARKET IN 2023	56
4.4	GEOGRAPHICAL GROWTH OPPORTUNITIES: CARRIER SCREENING MARKET	56
FIGURE 20	US TO REGISTER HIGHEST GROWTH RATE DURING STUDY PERIOD	56
5	MARKET OVERVIEW	57
5.1	INTRODUCTION	57
5.2	MARKET DYNAMICS	57
FIGURE 21	DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: CARRIER SCREENING MARKET	57
5.2.1	DRIVERS	58
5.2.1.1	Increasing emphasis on early disease detection and prevention	58
5.2.1.2	Growing prevalence of genetic disorders	58
5.2.1.3	High risk of chromosomal abnormalities with advancing maternal age	59

TABLE 2 □GLOBAL INCIDENCE RATE OF TRISOMY □59

5.2.1.4 □Increased focus on preconception and prenatal testing □59

5.2.1.5 □Rising number of fertility clinics and IVF centers □60

5.2.1.6 □Declining rate of fertility □60

TABLE 3 □FERTILITY RATE (BIRTHS PER WOMAN), BY COUNTRY □61

5.2.2 □RESTRAINTS □61

5.2.2.1 □Ethical concerns in preconception genetic carrier screening □61

5.2.2.2 □High cost of carrier screening □62

5.2.3 □OPPORTUNITIES □62

5.2.3.1 □Increased awareness about reproductive health in emerging economies □62

FIGURE 22 □HEALTHCARE EXPENDITURE PER CAPITA IN BRICS, 2012-2020 □63

5.2.3.2 □Integration with telehealth and digital health platforms □63

5.2.3.3 □Increased number of collaborations and partnerships among healthcare organizations □64

5.2.3.4 □Increasing number of government initiatives and policies toward genetic health improvement □64

5.2.3.5 □Growing focus on health screening for rare diseases □65

5.2.4 □CHALLENGES □65

5.2.4.1 □Lack of skilled professionals □65

5.2.4.2 □Lack of standard guidelines for carrier screening □65

5.3 □TRENDS □66

5.3.1 □LACK OF PUBLIC INTEREST IN EXPANDED CARRIER SCREENING □66

5.4 □PRICING ANALYSIS □66

TABLE 4 □INDICATIVE PRICING OF CARRIER SCREENING PRODUCTS/SERVICES □66

TABLE 5 □AVERAGE SELLING PRICE OF PREIMPLANTATION GENETIC TESTING SYSTEMS □67

5.5 □VALUE CHAIN ANALYSIS □67

FIGURE 23 □VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES □67

5.6 □SUPPLY CHAIN ANALYSIS □68

FIGURE 24 □SUPPLY CHAIN ANALYSIS: DIRECT DISTRIBUTION TO BE PREFERRED STRATEGY FOR PROMINENT COMPANIES □69

5.7 □PORTER'S FIVE FORCES ANALYSIS □69

TABLE 6 □PORTER'S FIVE FORCES: CARRIER SCREENING MARKET □69

5.7.1 □THREAT OF NEW ENTRANTS □69

5.7.2 □THREAT OF SUBSTITUTES □70

5.7.3 □BARGAINING POWER OF SUPPLIERS □70

5.7.4 □BARGAINING POWER OF BUYERS □70

5.7.5 □INTENSITY OF COMPETITIVE RIVALRY □70

5.8 □ECOSYSTEM/MARKET MAP □71

FIGURE 25 □ECOSYSTEM/MARKET MAP: CARRIER SCREENING MARKET □71

TABLE 7 □ROLE IN ECOSYSTEM: CARRIER SCREENING MARKET □71

FIGURE 26 □KEY PLAYERS IN CARRIER SCREENING MARKET □72

5.9 □TARIFF & REGULATORY LANDSCAPE □72

TABLE 8 □INDICATIVE LIST OF REGULATORY AUTHORITIES GOVERNING CARRIER SCREENING MARKET □72

5.9.1 □NORTH AMERICA □73

5.9.1.1 □US □73

5.9.1.2 □Canada □73

5.9.2 □EUROPE □73

5.9.2.1 □UK □73

5.9.2.2 □France □73

5.9.3 □ASIA PACIFIC □74

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.9.3.1	Japan	74
5.9.3.2	India	74
5.10	PATENT ANALYSIS	74
5.10.1	PATENT TRENDS FOR CARRIER SCREENING	74
	FIGURE 27	PATENT TRENDS FOR CARRIER SCREENING, JANUARY 2013-DECEMBER 2023
5.10.2	JURISDICTION AND TOP APPLICANT ANALYSIS	75
	FIGURE 28	TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR CARRIER SCREENING PATENTS, JANUARY 2013-DECEMBER 2023
5.11	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	75
5.11.1	REVENUE SHIFT AND REVENUE POCKETS FOR CARRIER SCREENING MANUFACTURERS	75
	FIGURE 29	REVENUE SHIFT FOR CARRIER SCREENING PRODUCTS/SERVICES
5.12	KEY CONFERENCES & EVENTS	76
	TABLE 9	DETAILED LIST OF KEY CONFERENCES & EVENTS, JANUARY 2024-DECEMBER 2025
5.13	TECHNOLOGY ANALYSIS	77
5.14	KEY STAKEHOLDERS & BUYING CRITERIA	78
5.14.1	KEY STAKEHOLDERS	78
	FIGURE 30	INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CARRIER SCREENING PRODUCTS
	TABLE 10	INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CARRIER SCREENING PRODUCTS (%)
5.14.2	BUYING CRITERIA	78
	FIGURE 31	KEY BUYING CRITERIA FOR END USERS OF CARRIER SCREENING PRODUCTS/SERVICES
	TABLE 11	KEY BUYING CRITERIA FOR END USERS OF CARRIER SCREENING PRODUCTS/SERVICES
5.15	TRADE ANALYSIS	79
	TABLE 12	IMPORT DATA FOR HS CODE 901849, BY COUNTRY, 2018-2022 (USD MILLION)
	TABLE 13	EXPORT DATA FOR HS CODE 901849, BY COUNTRY, 2018-2022 (USD MILLION)
6	CARRIER SCREENING MARKET, BY PRODUCT & SERVICE	80
6.1	INTRODUCTION	81
	TABLE 14	CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
6.2	SERVICES	81
6.2.1	RISING NUMBER OF ACCREDITED LABORATORIES AND GENETIC CASES TO DRIVE MARKET	81
	TABLE 15	CARRIER SCREENING MARKET FOR SERVICES, BY REGION, 2021-2028 (USD MILLION)
6.3	PRODUCTS	82
6.3.1	GROWING INCIDENCE OF CHROMOSOMAL ABNORMALITIES AND RISING USE OF CARRIER SCREENING TESTS TO DRIVE MARKET	82
	TABLE 16	KEY PLAYERS PROVIDING CARRIER SCREENING PRODUCTS
	TABLE 17	CARRIER SCREENING MARKET FOR PRODUCTS, BY REGION, 2021-2028 (USD MILLION)
7	CARRIER SCREENING MARKET, BY TYPE	84
7.1	INTRODUCTION	85
	TABLE 18	CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)
7.2	EXPANDED CARRIER SCREENING	85
	TABLE 19	CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)
	TABLE 20	CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY REGION, 2021-2028 (USD MILLION)
7.2.1	PREDESIGNED PANEL TESTING	86
7.2.1.1	Predesigned panel testing segment to command larger market share during forecast period	86
	TABLE 21	PREDESIGNED PANEL TESTING MARKET, BY REGION, 2021-2028 (USD MILLION)
7.2.2	CUSTOMIZED PANEL TESTING	88
7.2.2.1	Better customization options for meeting specific customer requirements to drive segment	88
	TABLE 22	CUSTOMIZED PANEL TESTING MARKET, BY REGION, 2021-2028 (USD MILLION)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

7.3	TARGETED DISEASE CARRIER SCREENING	89
7.3.1	INTRODUCTION OF PANELS FOR SIMULTANEOUSLY SCREENING MULTIPLE GENETIC CONDITIONS TO DRIVE MARKET	89
TABLE 23	CARRIER SCREENING MARKET FOR TARGETED DISEASE CARRIER SCREENING, BY REGION, 2021-2028 (USD MILLION)	89
8	CARRIER SCREENING MARKET, BY MEDICAL CONDITION	90
8.1	INTRODUCTION	91
TABLE 24	CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)	91
8.2	PULMONARY CONDITIONS	91
8.2.1	INCREASING AWARENESS ABOUT CYSTIC FIBROSIS IN REPRODUCTIVE PLANNING TO DRIVE MARKET	91
TABLE 25	LIVE BIRTH INCIDENCE OF CYSTIC FIBROSIS	92
TABLE 26	CARRIER SCREENING PRODUCTS/SERVICES FOR CYSTIC FIBROSIS	92
TABLE 27	CARRIER SCREENING MARKET FOR PULMONARY CONDITIONS, BY REGION, 2021-2028 (USD MILLION)	93
8.3	HEMATOLOGICAL CONDITIONS	93
8.3.1	RISING PREVALENCE OF HEMATOLOGICAL DISORDERS AMONG INFANTS TO DRIVE MARKET	93
TABLE 28	CARRIER SCREENING MARKET FOR HEMATOLOGICAL CONDITIONS, BY REGION, 2021-2028 (USD MILLION)	94
8.4	NEUROLOGICAL CONDITIONS	94
8.4.1	INCREASED AWARENESS OF NEUROLOGICAL SCREENING AND PRESENCE OF TARGETED SCREENING PANELS TO DRIVE MARKET	94
TABLE 29	GLOBAL PREVALENCE OF NEUROLOGICAL CONDITIONS	95
TABLE 30	CARRIER SCREENING PRODUCTS/SERVICES FOR NEUROLOGICAL CONDITIONS	95
TABLE 31	CARRIER SCREENING MARKET FOR NEUROLOGICAL CONDITIONS, BY REGION, 2021-2028 (USD MILLION)	96
8.5	OTHER MEDICAL CONDITIONS	96
TABLE 32	CARRIER SCREENING MARKET FOR OTHER MEDICAL CONDITIONS, BY REGION, 2021-2028 (USD MILLION)	97
9	CARRIER SCREENING MARKET, BY TECHNOLOGY	98
9.1	INTRODUCTION	99
TABLE 33	CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	99
9.2	DNA SEQUENCING	99
9.2.1	DNA SEQUENCING SEGMENT TO DOMINATE MARKET DURING STUDY PERIOD	99
TABLE 34	DNA SEQUENCING USED BY MARKET PLAYERS	100
TABLE 35	CARRIER SCREENING MARKET FOR DNA SEQUENCING, BY REGION, 2021-2028 (USD MILLION)	100
9.3	PCR	101
9.3.1	HIGH ACCURACY, LOW REACTION TIME, AND ABSOLUTE ESTIMATION OF TARGET MOLECULE TO DRIVE MARKET	101
TABLE 36	PCR USED BY MARKET PLAYERS	101
TABLE 37	CARRIER SCREENING MARKET FOR PCR, BY REGION, 2021-2028 (USD MILLION)	101
9.4	DNA MICROARRAYS	102
9.4.1	ABILITY TO ANALYZE MULTIPLE GENETIC MARKERS IN SINGLE ASSAY TO DRIVE MARKET	102
TABLE 38	DNA MICROARRAYS USED BY MARKET PLAYERS	102
TABLE 39	CARRIER SCREENING MARKET FOR DNA MICROARRAYS, BY REGION, 2021-2028 (USD MILLION)	102
9.5	OTHER TECHNOLOGIES	103
TABLE 40	ADVANTAGES OF OTHER TECHNOLOGIES FOR CARRIER SCREENING	103
TABLE 41	CARRIER SCREENING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021-2028 (USD MILLION)	103
10	CARRIER SCREENING MARKET, BY END USER	104
10.1	INTRODUCTION	105
TABLE 42	CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)	105
10.2	HOSPITALS AND MEDICAL CENTERS	105
10.2.1	RISING PATIENT POPULATION AND INCREASING MEDICARE REIMBURSEMENT FOR CLINICAL TESTS TO DRIVE SEGMENT	105
TABLE 43	CARRIER SCREENING MARKET FOR HOSPITALS AND MEDICAL CENTERS, BY REGION, 2021-2028 (USD MILLION)	106
10.3	CLINICAL LABORATORIES	106

10.3.1	LOWER SERVICE COSTS AND HIGHER TURNAROUND TIME TO DRIVE MARKET	106
TABLE 44	CARRIER SCREENING MARKET FOR CLINICAL LABORATORIES, BY REGION, 2021-2028 (USD MILLION)	107
10.4	FERTILITY CLINICS	107
10.4.1	INCREASING NUMBER OF INFERTILE COUPLES AND GROWING MEDICAL TOURISM IN EMERGING ECONOMIES TO DRIVE MARKET	107
TABLE 45	CARRIER SCREENING MARKET FOR FERTILITY CLINICS, BY REGION, 2021-2028 (USD MILLION)	108
10.5	OTHER END USERS	108
TABLE 46	CARRIER SCREENING MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD MILLION)	109
11	CARRIER SCREENING MARKET, BY REGION	110
11.1	INTRODUCTION	111
TABLE 47	CARRIER SCREENING MARKET, BY REGION, 2021-2028 (USD MILLION)	111
11.2	NORTH AMERICA	111
FIGURE 32	NORTH AMERICA: CARRIER SCREENING MARKET SNAPSHOT	112
TABLE 48	NORTH AMERICA: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	113
TABLE 49	NORTH AMERICA: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)	113
TABLE 50	NORTH AMERICA: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)	113
TABLE 51	NORTH AMERICA: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	114
TABLE 52	NORTH AMERICA: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)	114
TABLE 53	NORTH AMERICA: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)	115
TABLE 54	NORTH AMERICA: CARRIER SCREENING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	115
11.2.1	NORTH AMERICA: RECESSION IMPACT	115
11.2.2	US	116
11.2.2.1	Increasing number of genetic diseases and rising healthcare expenditure to drive market	116
TABLE 55	US: KEY MACROINDICATORS	117
TABLE 56	US: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	117
TABLE 57	US: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)	118
TABLE 58	US: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)	118
TABLE 59	US: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	118
TABLE 60	US: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)	119
TABLE 61	US: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)	119
11.2.3	CANADA	119
11.2.3.1	Increasing government and non-government funding to drive market	119
TABLE 62	CANADA: KEY MACROINDICATORS	120
TABLE 63	CANADA: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	121
TABLE 64	CANADA: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)	121
TABLE 65	CANADA: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)	121
TABLE 66	CANADA: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	122
TABLE 67	CANADA: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)	122
TABLE 68	CANADA: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)	122
11.3	EUROPE	123
TABLE 69	EUROPE: HEALTHCARE EXPENDITURE, BY COUNTRY (% OF GDP)	123
11.3.1	EUROPE: RECESSION IMPACT	124
TABLE 70	EUROPE: CARRIER SCREENING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	124
TABLE 71	EUROPE: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	125
TABLE 72	EUROPE: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)	125
TABLE 73	EUROPE: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)	125

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)



TABLE 74	EUROPE: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	126
TABLE 75	EUROPE: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)	126
TABLE 76	EUROPE: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)	126
11.3.2	GERMANY	127
11.3.2.1	Increasing number of government initiatives and healthcare expenditures to drive market	127
TABLE 77	GERMANY: KEY MACROINDICATORS	128
TABLE 78	GERMANY: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	128
TABLE 79	GERMANY: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)	128
TABLE 80	GERMANY: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)	129
TABLE 81	GERMANY: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	129
TABLE 82	GERMANY: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)	129
TABLE 83	GERMANY: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)	130
11.3.3	UK	130
11.3.3.1	Rising prevalence of hematological disease and increasing number of accredited clinical laboratories to drive market	130
TABLE 84	UK: KEY MACROINDICATORS	131
TABLE 85	UK: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	131
TABLE 86	UK: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)	131
TABLE 87	UK: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)	132
TABLE 88	UK: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	132
TABLE 89	UK: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)	132
TABLE 90	UK: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)	133
11.3.4	FRANCE	133
11.3.4.1	Better healthcare infrastructure and higher expenditure for life science research to drive market	133
TABLE 91	FRANCE: KEY MACROINDICATORS	134
TABLE 92	FRANCE: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	134
TABLE 93	FRANCE: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)	134
TABLE 94	FRANCE: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)	135
TABLE 95	FRANCE: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	135
TABLE 96	FRANCE: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)	135
TABLE 97	FRANCE: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)	136
11.3.5	ITALY	136
11.3.5.1	Growing prevalence of chronic diseases and rising number of hospitals to drive market	136
TABLE 98	ITALY: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	137
TABLE 99	ITALY: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)	137
TABLE 100	ITALY: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)	137
TABLE 101	ITALY: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	138
TABLE 102	ITALY: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)	138
TABLE 103	ITALY: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)	138
11.3.6	SPAIN	139
11.3.6.1	Increasing prevalence of rare genetic diseases and rising availability of research funding to drive market	139
TABLE 104	SPAIN: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	139
TABLE 105	SPAIN: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)	140
TABLE 106	SPAIN: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)	140
TABLE 107	SPAIN: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	140
TABLE 108	SPAIN: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)	141
TABLE 109	SPAIN: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)	141
11.3.7	REST OF EUROPE	141

TABLE 110	REST OF EUROPE: HEALTHCARE EXPENDITURE, BY COUNTRY, 2010 VS. 2021 (% OF GDP)	142
TABLE 111	REST OF EUROPE: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	142
TABLE 112	REST OF EUROPE: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)	142
TABLE 113	REST OF EUROPE: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)	143
TABLE 114	REST OF EUROPE: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	143
TABLE 115	REST OF EUROPE: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)	143
TABLE 116	REST OF EUROPE: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)	144
11.4	ASIA PACIFIC	144
11.4.1	ASIA PACIFIC: RECESSION IMPACT	145
FIGURE 33	ASIA PACIFIC: CARRIER SCREENING MARKET SNAPSHOT	146
TABLE 117	ASIA PACIFIC: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	146
TABLE 118	ASIA PACIFIC: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)	147
TABLE 119	ASIA PACIFIC: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)	147
TABLE 120	ASIA PACIFIC: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	147
TABLE 121	ASIA PACIFIC: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)	148
TABLE 122	ASIA PACIFIC: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)	148
11.4.2	INDIA	148
11.4.2.1	Growing incidence of rare diseases and declining fertility rates to drive market	148
TABLE 123	INDIA: KEY MACROINDICATORS	149
TABLE 124	INDIA: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	149
TABLE 125	INDIA: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)	150
TABLE 126	INDIA: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)	150
TABLE 127	INDIA: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	150
TABLE 128	INDIA: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)	151
TABLE 129	INDIA: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)	151
11.4.3	CHINA	151
11.4.3.1	Rising focus on vaccine development and cancer research to drive market	151
TABLE 130	CHINA: KEY MACROINDICATORS	152
TABLE 131	CHINA: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	152
TABLE 132	CHINA: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)	153
TABLE 133	CHINA: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)	153
TABLE 134	CHINA: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	153
TABLE 135	CHINA: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)	154
TABLE 136	CHINA: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)	154
11.4.4	JAPAN	154
11.4.4.1	Rising geriatric population and growing government healthcare expenditure to drive market	154
TABLE 137	JAPAN: KEY MACROINDICATORS	155
TABLE 138	JAPAN: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	156
TABLE 139	JAPAN: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)	156
TABLE 140	JAPAN: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)	156
TABLE 141	JAPAN: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	157
TABLE 142	JAPAN: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)	157
TABLE 143	JAPAN: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)	157
11.4.5	REST OF ASIA PACIFIC	158
TABLE 144	REST OF ASIA PACIFIC: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	159

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

TABLE 145	REST OF ASIA PACIFIC: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)	159
TABLE 146	REST OF ASIA PACIFIC: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)	159
TABLE 147	REST OF ASIA PACIFIC: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	160
TABLE 148	REST OF ASIA PACIFIC: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)	160
TABLE 149	REST OF ASIA PACIFIC: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)	161
11.5	REST OF THE WORLD	161
11.5.1	REST OF THE WORLD: RECESSION IMPACT	162
TABLE 150	REST OF THE WORLD: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	162
TABLE 151	REST OF THE WORLD: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)	162
TABLE 152	REST OF THE WORLD: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)	163
TABLE 153	REST OF THE WORLD: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	163
TABLE 154	REST OF THE WORLD: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)	163
TABLE 155	REST OF THE WORLD: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)	164
11.5.2	LATIN AMERICA	164
11.5.2.1	Higher prevalence of genetic disorders and growing focus on reproductive healthcare services to drive market	164
TABLE 156	DEFINITION OF RARE DISEASES IN VARIOUS COUNTRIES	164
TABLE 157	LATIN AMERICA: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	165
TABLE 158	LATIN AMERICA: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)	165
TABLE 159	LATIN AMERICA: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)	166
TABLE 160	LATIN AMERICA: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	166
TABLE 161	LATIN AMERICA: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)	166
TABLE 162	LATIN AMERICA: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)	167
11.5.3	MIDDLE EAST & AFRICA	167
TABLE 163	MIDDLE EAST & AFRICA: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	168
TABLE 164	MIDDLE EAST & AFRICA: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)	168
TABLE 165	MIDDLE EAST & AFRICA: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)	168
TABLE 166	MIDDLE EAST & AFRICA: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	169
TABLE 167	MIDDLE EAST & AFRICA: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)	169
TABLE 168	MIDDLE EAST & AFRICA: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)	170
11.5.3.1	GCC Countries	170
11.5.3.1.1	Improved healthcare infrastructure and launch of genome projects to drive market	170
TABLE 169	GCC COUNTRIES: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	171
TABLE 170	GCC COUNTRIES: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)	171
TABLE 171	GCC COUNTRIES: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)	172
TABLE 172	GCC COUNTRIES: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	172
TABLE 173	GCC COUNTRIES: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)	172
TABLE 174	GCC COUNTRIES: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)	173
12	COMPETITIVE LANDSCAPE	174
12.1	OVERVIEW	174
12.2	KEY STRATEGIES/RIGHT TO WIN	174
12.2.1	OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS	174
TABLE 175	OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CARRIER SCREENING MARKET	174

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

12.3	MARKET SHARE ANALYSIS	175
TABLE 176	DEGREE OF COMPETITION: CARRIER SCREENING MARKET	175
12.4	REVENUE SHARE ANALYSIS	175
FIGURE 34	REVENUE SHARE ANALYSIS OF KEY PLAYERS	176
12.5	COMPANY EVALUATION MATRIX	177
12.5.1	STARS	177
12.5.2	EMERGING LEADERS	177
12.5.3	PERVASIVE PLAYERS	177
12.5.4	PARTICIPANTS	177
FIGURE 35	COMPANY EVALUATION MATRIX, 2022	178
12.5.5	COMPANY FOOTPRINT	178
TABLE 177	OVERALL COMPANY FOOTPRINT	178
TABLE 178	PRODUCT FOOTPRINT	179
TABLE 179	REGIONAL FOOTPRINT	180
12.6	START-UP/SME EVALUATION MATRIX	181
12.6.1	PROGRESSIVE COMPANIES	181
12.6.2	RESPONSIVE COMPANIES	181
12.6.3	DYNAMIC COMPANIES	181
12.6.4	STARTING BLOCKS	182
FIGURE 36	START-UP/SME EVALUATION MATRIX, 2022	182
12.6.5	COMPETITIVE BENCHMARKING	182
TABLE 180	DETAILED LIST OF KEY START-UPS/SMES IN CARRIER SCREENING MARKET	182
12.7	COMPETITIVE SCENARIOS AND TRENDS	183
12.7.1	KEY DEALS	183
TABLE 181	KEY DEALS, JANUARY 2020-DECEMBER 2023	183
13	COMPANY PROFILES	184
13.1	KEY PLAYERS	184
(Business overview, Products/Services/Solutions offered, Recent developments, MnM view, Key strengths/Right to win, Strategic choices made, and Weaknesses and Competitive threats)*		
13.1.1	NATERA, INC.	184
TABLE 182	NATERA, INC.: COMPANY OVERVIEW	184
FIGURE 37	NATERA, INC.: COMPANY SNAPSHOT (2022)	185
13.1.2	QUEST DIAGNOSTICS INCORPORATED	187
TABLE 183	QUEST DIAGNOSTICS INCORPORATED: COMPANY OVERVIEW	187
FIGURE 38	QUEST DIAGNOSTICS INCORPORATED: COMPANY SNAPSHOT (2022)	187
13.1.3	FULGENT GENETICS	189
TABLE 184	FULGENT GENETICS: COMPANY OVERVIEW	189
FIGURE 39	FULGENT GENETICS.: COMPANY SNAPSHOT (2022)	190
13.1.4	INVITAE CORPORATION	192
TABLE 185	INVITAE CORPORATION: COMPANY OVERVIEW	192
FIGURE 40	INVITAE CORPORATION.: COMPANY SNAPSHOT (2022)	193
13.1.5	EUROFINS SCIENTIFIC	195
TABLE 186	EUROFINS SCIENTIFIC: COMPANY OVERVIEW	195
FIGURE 41	EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2022)	195
13.1.6	OPKO HEALTH, INC.	197
TABLE 187	OPKO HEALTH, INC.: COMPANY OVERVIEW	197
FIGURE 42	OPKO HEALTH, INC.: COMPANY SNAPSHOT (2022)	198

13.1.7	THERMO FISHER SCIENTIFIC INC.	200
TABLE 188	THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW	200
FIGURE 43	THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)	201
13.1.8	MYRIAD GENETICS, INC.	202
TABLE 189	MYRIAD GENETICS, INC.: COMPANY OVERVIEW	202
FIGURE 44	MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2022)	203
13.1.9	ILLUMINA, INC.	204
TABLE 190	ILLUMINA, INC.: COMPANY OVERVIEW	204
FIGURE 45	ILLUMINA, INC.: COMPANY SNAPSHOT (2022)	205
13.1.10	LABORATORY CORPORATION OF AMERICA HOLDINGS	206
TABLE 191	LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY OVERVIEW	206
FIGURE 46	LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2022)	207
13.1.11	CENTOGENE N.V.	209
TABLE 192	CENTOGENE N.V.: COMPANY OVERVIEW	209
FIGURE 47	CENTOGENE N.V.: COMPANY SNAPSHOT (2022)	210
13.1.12	DIASORIN S.P.A.	211
TABLE 193	DIASORIN S.P.A.: COMPANY OVERVIEW	211
FIGURE 48	DIASORIN S.P.A.: COMPANY SNAPSHOT (2023)	212
13.1.13	BGI	213
TABLE 194	BGI: COMPANY OVERVIEW	213
13.1.14	OTOGENETICS	214
TABLE 195	OTOGENETICS: COMPANY OVERVIEW	214
13.1.15	GENETECH	215
TABLE 196	GENETECH: COMPANY OVERVIEW	215
13.2	OTHER PLAYERS	216
13.2.1	OXY-GEN LABORATORY LLC	216
TABLE 197	OXY-GEN LABORATORY LLC: COMPANY OVERVIEW	216
13.2.2	MEDGENOME	217
TABLE 198	MEDGENOME: COMPANY OVERVIEW	217
13.2.3	AMBRY GENETICS	218
TABLE 199	AMBRY GENETICS: COMPANY OVERVIEW	218
13.2.4	ASPER BIOGENE	219
TABLE 200	ASPER BIOGENE: COMPANY OVERVIEW	219
13.2.5	LIFELABS GENETICS	220
TABLE 201	LIFELABS GENETICS: COMPANY OVERVIEW	220
13.2.6	EASYDNA	221
TABLE 202	EASYDNA: COMPANY OVERVIEW	221
13.2.7	LIFECCELL	222
TABLE 203	LIFECCELL: COMPANY OVERVIEW	222
13.2.8	CNC PATH LAB	223
TABLE 204	CNC PATH LAB: COMPANY OVERVIEW	223
13.2.9	SIGNATURE DIAGNOSTICS INC.	224
TABLE 205	SIGNATURE DIAGNOSTICS INC.: COMPANY OVERVIEW	224
13.2.10	MITERA	225
TABLE 206	MITERA: COMPANY OVERVIEW	225

\*Details on Business overview, Products/Services/Solutions offered, Recent developments, MnM view, Key strengths/Right to win, Strategic choices made, and Weaknesses and Competitive threats might not be captured in case of unlisted companies.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

14	APPENDIX	226
14.1	DISCUSSION GUIDE	226
14.2	KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL	229
14.3	CUSTOMIZATION OPTIONS	231
14.4	RELATED REPORTS	231
14.5	AUTHOR DETAILS	232

**Carrier Screening Market by Product and Service, Type (Expanded (Customized, Predesigned) Targeted Diseases, Medical condition (Hematologic, Pulmonary), Technology (DNA Sequencing, PCR), End user, Region - Global Forecast to 2028**

Market Report | 2024-01-31 | 224 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Date

2025-05-20

Signature



**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)